Ryckelynck J P, Heron J F, Juret P, Schneider P, Herlin P, De Ranieri E, Hardouin A, Peny J, Le Talaer J Y
Nephrologie. 1984;5(2):59-63.
9-hydroxy-2-methyl-ellipticinium (HME) is an intercaling agent mainly potent in metastatic breast cancer. Its almost complete lack of bone marrow toxicity is of greatest value. However, among 385 patients 20 cases of renal failure were observed: renal failure is gradual, non reversible except in four cases with acute renal failure. Histological and ultrastructural studies, performed in 8 cases, showed exclusively proximal tubular lesions, without glomerular or interstitial lesions. We have evidence that there is a relation between the cumulative dose and the severity of the lesions. A prospective study was done in 30 patients. An increase in enzymuria, proteinuria and glycosuria was observed in most patients after HME infusion. HME is an efficient drug in the treatment of bone metastases of breast cancer. Renal function should be carefully monitored during HME administration.
9-羟基-2-甲基玫瑰树碱（HME）是一种主要对转移性乳腺癌有效的嵌入剂。其几乎完全没有骨髓毒性，这具有极大的价值。然而，在385例患者中观察到20例肾衰竭：肾衰竭是渐进性的，除4例急性肾衰竭外均不可逆。对8例患者进行的组织学和超微结构研究仅显示近端肾小管病变，无肾小球或间质病变。我们有证据表明累积剂量与病变严重程度之间存在关联。对30例患者进行了一项前瞻性研究。大多数患者在输注HME后出现酶尿、蛋白尿和糖尿增加。HME是治疗乳腺癌骨转移的有效药物。在给予HME期间应仔细监测肾功能。
